Kura Oncology公布了其Darlifarnib联合卡博替尼方案,在未接受过卡博替尼治疗的透明细胞肾细胞癌患者中,展现出持久的临床活性。该研究结果于2026年KCRS大会上正式披露。
Kura Oncology公布了其Darlifarnib联合卡博替尼方案,在未接受过卡博替尼治疗的透明细胞肾细胞癌患者中,展现出持久的临床活性。该研究结果于2026年KCRS大会上正式披露。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.